Patient group input submissions Ixekizumab (Taltz) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
Two questionnaires (February & March 2016) were promoted via CSPA's social media channels to psoriasis patients or those suffering with psoriasis related symptoms (44 surveys received) to gather input on the effectiveness of ixekizumab in the treatment of the disease.
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820271706719 |
| Sumario: | Two questionnaires (February & March 2016) were promoted via CSPA's social media channels to psoriasis patients or those suffering with psoriasis related symptoms (44 surveys received) to gather input on the effectiveness of ixekizumab in the treatment of the disease. |
|---|---|
| Descripción Física: | 1 online resource (7 pages) |
